{"id":7487,"date":"2017-08-18T05:31:40","date_gmt":"2017-08-18T05:31:40","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-annonce-que-son-partenaire-licencie-exclusif-mondial-depose-un-memoire-relatif-la-lettre-de-reponse-complete-response-letter-pour-la-solution-ophtalmique-de-latanoprostene-bunod-0024\/"},"modified":"2017-08-18T05:31:40","modified_gmt":"2017-08-18T05:31:40","slug":"nicox-annonce-que-son-partenaire-licencie-exclusif-mondial-depose-un-memoire-relatif-la-lettre-de-reponse-complete-response-letter-pour-la-solution-ophtalmique-de-latanoprostene-bunod-0024","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-annonce-que-son-partenaire-licencie-exclusif-mondial-depose-un-memoire-relatif-la-lettre-de-reponse-complete-response-letter-pour-la-solution-ophtalmique-de-latanoprostene-bunod-0024\/","title":{"rendered":"Nicox annonce que son partenaire licenci\u00e9 exclusif mondial a d\u00e9pos\u00e9 un m\u00e9moire relatif \u00e0 la lettre de r\u00e9ponse (Complete Response Letter) pour la solution ophtalmique de latanoprost\u00e8ne bunod, 0,024%"},"content":{"rendered":"<p>Sophia Antipolis, France<\/p>\n<p><strong>Nicox S.A.<\/strong> (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire licenci\u00e9 exclusif mondial l&rsquo;a inform\u00e9 avoir d\u00e9pos\u00e9 un m\u00e9moire concernant la lettre de r\u00e9ponse (<em>Complete Response Letter<\/em>, CRL) re\u00e7ue de la <em>Food and Drug Administration<\/em> (FDA) am\u00e9ricaine le 7 ao\u00fbt 2017 relative \u00e0 la demande d&rsquo;autorisation de mise sur le march\u00e9 (<em>New Drug Application<\/em>, NDA) pour la solution ophtalmique de latanoprost\u00e8ne bunod, 0,024% pour la r\u00e9duction de la pression intraoculaire chez les patients atteints de glaucome \u00e0 angle ouvert ou d&rsquo;hypertension oculaire.<\/p>\n<h4>A propos du latanoprost\u00e8ne bunod<\/h4>\n<p>Le latanoprost\u00e8ne bunod est un collyre oculaire en monoth\u00e9rapie avec une th\u00e9rapie \u00e0 double action. Lors de l&rsquo;instillation dans l&rsquo;\u0153il, le latanoprost\u00e8ne bunod fonctionne en m\u00e9tabolisant en deux substances actives, l&rsquo;acide de latanoprost et le mononitrate de butanediol, chacun ciblant une voie sp\u00e9cifique; le premier, l&rsquo;acide de latanoprost, un analogue de la prostaglandine F2-alpha, fonctionne principalement dans la voie uveoscl\u00e9rale pour augmenter l&rsquo;\u00e9coulement de l&rsquo;humeur aqueuse et le second, le mononitrate de butanediol, lib\u00e8re de l&rsquo;oxyde nitrique pour augmenter l\u2019\u00e9coulement \u00e0 travers le r\u00e9seau trab\u00e9culaire\/ canal de Schlemm.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sophia Antipolis, France Nicox S.A. (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire licenci\u00e9 exclusif mondial l&rsquo;a inform\u00e9 avoir d\u00e9pos\u00e9 un m\u00e9moire concernant la lettre de r\u00e9ponse (Complete Response Letter, CRL) re\u00e7ue de la Food and Drug Administration (FDA) am\u00e9ricaine le 7 ao\u00fbt 2017 relative \u00e0 [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-7487","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox annonce que son partenaire licenci\u00e9 exclusif mondial a d\u00e9pos\u00e9 un m\u00e9moire relatif \u00e0 la lettre de r\u00e9ponse (Complete Response Letter) pour la solution ophtalmique de latanoprost\u00e8ne bunod, 0,024% - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-annonce-que-son-partenaire-licencie-exclusif-mondial-depose-un-memoire-relatif-la-lettre-de-reponse-complete-response-letter-pour-la-solution-ophtalmique-de-latanoprostene-bunod-0024\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox annonce que son partenaire licenci\u00e9 exclusif mondial a d\u00e9pos\u00e9 un m\u00e9moire relatif \u00e0 la lettre de r\u00e9ponse (Complete Response Letter) pour la solution ophtalmique de latanoprost\u00e8ne bunod, 0,024% - Nicox\" \/>\n<meta property=\"og:description\" content=\"Sophia Antipolis, France Nicox S.A. (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire licenci\u00e9 exclusif mondial l&rsquo;a inform\u00e9 avoir d\u00e9pos\u00e9 un m\u00e9moire concernant la lettre de r\u00e9ponse (Complete Response Letter, CRL) re\u00e7ue de la Food and Drug Administration (FDA) am\u00e9ricaine le 7 ao\u00fbt 2017 relative \u00e0 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-annonce-que-son-partenaire-licencie-exclusif-mondial-depose-un-memoire-relatif-la-lettre-de-reponse-complete-response-letter-pour-la-solution-ophtalmique-de-latanoprostene-bunod-0024\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2017-08-18T05:31:40+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-annonce-que-son-partenaire-licencie-exclusif-mondial-depose-un-memoire-relatif-la-lettre-de-reponse-complete-response-letter-pour-la-solution-ophtalmique-de-latanoprostene-bunod-0024\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-annonce-que-son-partenaire-licencie-exclusif-mondial-depose-un-memoire-relatif-la-lettre-de-reponse-complete-response-letter-pour-la-solution-ophtalmique-de-latanoprostene-bunod-0024\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox annonce que son partenaire licenci\u00e9 exclusif mondial a d\u00e9pos\u00e9 un m\u00e9moire relatif \u00e0 la lettre de r\u00e9ponse (Complete Response Letter) pour la solution ophtalmique de latanoprost\u00e8ne bunod, 0,024%\",\"datePublished\":\"2017-08-18T05:31:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-annonce-que-son-partenaire-licencie-exclusif-mondial-depose-un-memoire-relatif-la-lettre-de-reponse-complete-response-letter-pour-la-solution-ophtalmique-de-latanoprostene-bunod-0024\\\/\"},\"wordCount\":246,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-annonce-que-son-partenaire-licencie-exclusif-mondial-depose-un-memoire-relatif-la-lettre-de-reponse-complete-response-letter-pour-la-solution-ophtalmique-de-latanoprostene-bunod-0024\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-annonce-que-son-partenaire-licencie-exclusif-mondial-depose-un-memoire-relatif-la-lettre-de-reponse-complete-response-letter-pour-la-solution-ophtalmique-de-latanoprostene-bunod-0024\\\/\",\"name\":\"Nicox annonce que son partenaire licenci\u00e9 exclusif mondial a d\u00e9pos\u00e9 un m\u00e9moire relatif \u00e0 la lettre de r\u00e9ponse (Complete Response Letter) pour la solution ophtalmique de latanoprost\u00e8ne bunod, 0,024% - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2017-08-18T05:31:40+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-annonce-que-son-partenaire-licencie-exclusif-mondial-depose-un-memoire-relatif-la-lettre-de-reponse-complete-response-letter-pour-la-solution-ophtalmique-de-latanoprostene-bunod-0024\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox annonce que son partenaire licenci\u00e9 exclusif mondial a d\u00e9pos\u00e9 un m\u00e9moire relatif \u00e0 la lettre de r\u00e9ponse (Complete Response Letter) pour la solution ophtalmique de latanoprost\u00e8ne bunod, 0,024% - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-annonce-que-son-partenaire-licencie-exclusif-mondial-depose-un-memoire-relatif-la-lettre-de-reponse-complete-response-letter-pour-la-solution-ophtalmique-de-latanoprostene-bunod-0024\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox annonce que son partenaire licenci\u00e9 exclusif mondial a d\u00e9pos\u00e9 un m\u00e9moire relatif \u00e0 la lettre de r\u00e9ponse (Complete Response Letter) pour la solution ophtalmique de latanoprost\u00e8ne bunod, 0,024% - Nicox","og_description":"Sophia Antipolis, France Nicox S.A. (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire licenci\u00e9 exclusif mondial l&rsquo;a inform\u00e9 avoir d\u00e9pos\u00e9 un m\u00e9moire concernant la lettre de r\u00e9ponse (Complete Response Letter, CRL) re\u00e7ue de la Food and Drug Administration (FDA) am\u00e9ricaine le 7 ao\u00fbt 2017 relative \u00e0 [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/nicox-annonce-que-son-partenaire-licencie-exclusif-mondial-depose-un-memoire-relatif-la-lettre-de-reponse-complete-response-letter-pour-la-solution-ophtalmique-de-latanoprostene-bunod-0024\/","og_site_name":"Nicox","article_published_time":"2017-08-18T05:31:40+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-annonce-que-son-partenaire-licencie-exclusif-mondial-depose-un-memoire-relatif-la-lettre-de-reponse-complete-response-letter-pour-la-solution-ophtalmique-de-latanoprostene-bunod-0024\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-annonce-que-son-partenaire-licencie-exclusif-mondial-depose-un-memoire-relatif-la-lettre-de-reponse-complete-response-letter-pour-la-solution-ophtalmique-de-latanoprostene-bunod-0024\/"},"author":{"name":"","@id":""},"headline":"Nicox annonce que son partenaire licenci\u00e9 exclusif mondial a d\u00e9pos\u00e9 un m\u00e9moire relatif \u00e0 la lettre de r\u00e9ponse (Complete Response Letter) pour la solution ophtalmique de latanoprost\u00e8ne bunod, 0,024%","datePublished":"2017-08-18T05:31:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-annonce-que-son-partenaire-licencie-exclusif-mondial-depose-un-memoire-relatif-la-lettre-de-reponse-complete-response-letter-pour-la-solution-ophtalmique-de-latanoprostene-bunod-0024\/"},"wordCount":246,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-annonce-que-son-partenaire-licencie-exclusif-mondial-depose-un-memoire-relatif-la-lettre-de-reponse-complete-response-letter-pour-la-solution-ophtalmique-de-latanoprostene-bunod-0024\/","url":"https:\/\/www.nicox.com\/fr\/nicox-annonce-que-son-partenaire-licencie-exclusif-mondial-depose-un-memoire-relatif-la-lettre-de-reponse-complete-response-letter-pour-la-solution-ophtalmique-de-latanoprostene-bunod-0024\/","name":"Nicox annonce que son partenaire licenci\u00e9 exclusif mondial a d\u00e9pos\u00e9 un m\u00e9moire relatif \u00e0 la lettre de r\u00e9ponse (Complete Response Letter) pour la solution ophtalmique de latanoprost\u00e8ne bunod, 0,024% - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2017-08-18T05:31:40+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-annonce-que-son-partenaire-licencie-exclusif-mondial-depose-un-memoire-relatif-la-lettre-de-reponse-complete-response-letter-pour-la-solution-ophtalmique-de-latanoprostene-bunod-0024\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=7487"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7487\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=7487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=7487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=7487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}